Literature DB >> 30582992

The uses of naltrexone in dermatologic conditions.

Brigette Lee1, Dirk M Elston2.   

Abstract

BACKGROUND: Naltrexone in standard and reduced doses is efficacious in many inflammatory and acantholytic disorders.
OBJECTIVE: We summarized the current data of naltrexone that are relevant to dermatologic practice.
METHODS: An English language PubMed literature search was performed using the terms naltrexone, low-dose naltrexone, Hailey-Hailey, psoriasis, lichen planopilaris, alopecia, opioid, opioid receptor, treatment, dermatology, monitoring, side effect, skin, pruritus, cutaneous, acantholytic, and Darier.
RESULTS: Opioid receptors are found throughout the skin and affect cell proliferation, migration, and adhesion. μ Opioid receptors have been found in all layers of the epidermis, while δ receptors are concentrated at cell junctions and can reduce desmoglein expression. Typical doses of naltrexone result in continuous binding to receptors. Low doses result in intermittent blockade with increased ligand and receptor expression, potentiating their effect. LIMITATIONS: Our review was restricted to the English language literature.
CONCLUSION: Naltrexone affects inflammation, cell adhesion, and keratinocyte proliferation and migration. While low-dose naltrexone has demonstrated efficacy in treating patients with Hailey-Hailey disease, further dose-ranging studies are needed. Data suggest that naltrexone could be helpful in the treatment of pruritus and a variety of inflammatory and acantholytic skin diseases that are refractory to other treatments. At higher doses, liver function tests should be monitored on a periodic basis.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hailey–Hailey disease; dermatology; lichen planopilaris; low-dose naltrexone; naltrexone; opioid receptor; opioid receptor antagonist; opioids; pruritus; psoriasis; scleroderma

Mesh:

Substances:

Year:  2018        PMID: 30582992     DOI: 10.1016/j.jaad.2018.12.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  Management of Darier disease: A review of the literature and update.

Authors:  Roger N Haber; Nicole G Dib
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

Review 2.  Opioidergic Signaling-A Neglected, Yet Potentially Important Player in Atopic Dermatitis.

Authors:  Dorottya Ádám; József Arany; Kinga Fanni Tóth; Balázs István Tóth; Attila Gábor Szöllősi; Attila Oláh
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 3.  A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris.

Authors:  Katerina Svigos; Lu Yin; Lauren Fried; Kristen Lo Sicco; Jerry Shapiro
Journal:  Am J Clin Dermatol       Date:  2021-08-04       Impact factor: 7.403

4.  Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report.

Authors:  Darosa Lim; Annie Belisle; Sandra Davar
Journal:  SAGE Open Med Case Rep       Date:  2020-12-25

5.  VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody.

Authors:  Laura Micheli; Carmen Parisio; Elena Lucarini; Alessia Vona; Alessandra Toti; Alessandra Pacini; Tommaso Mello; Serena Boccella; Flavia Ricciardi; Sabatino Maione; Grazia Graziani; Pedro Miguel Lacal; Paola Failli; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  J Exp Clin Cancer Res       Date:  2021-10-14

6.  A Case of Darier's Disease with a Novel Missense Mutation in ATP2A2 Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound Ointment.

Authors:  Teppei Hagino; Hajime Nakano; Hidehisa Saeki; Naoko Kanda
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-05

Review 7.  Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects.

Authors:  Hao-Jui Weng; Quoc Thao Trang Pham; Chia-Wei Chang; Tsen-Fang Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-19

8.  Exacerbation of Galli-Galli Disease Following Dialysis Treatment: A Case Report and Review of Aggravating Factors.

Authors:  Tejas P Joshi; Sally Shaver; Jaime Tschen
Journal:  Cureus       Date:  2021-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.